![George Lloyd](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
George Lloyd
Chief Investment Officer bei
RP Management LLC
Vermögen: 573 Mio $ am 31.05.2026
Profil
Derzeit hat George Lloyd die Position des Executive VP-Investments & General Counsel bei RP Management LLC und Executive VP-Investments & General Counsel bei Royalty Pharma Plc inne. Er ist auch im Vorstand von Royalty Pharma Holdings Ltd. In der Vergangenheit war er Partner bei Goodwin Procter LLP, Associate bei Davis Polk & Wardwell LLP und Partner bei Testa, Hurwitz & Thibeault LLP. Er erhielt einen Bachelor-Abschluss von der Princeton University und einen Master-Abschluss von der New York Law School.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
RPI US Partners 2019 LP
 RPI US Partners 2019 LP Financial ConglomeratesFinance Functions as an investment fund 3,53 % | 08.08.2025 | 7.527.320 ( 3,53 % ) | 420 Mio $ | 31.05.2026 |
ROYALTY PHARMA PLC 7,93 % | 16.05.2025 | 1.944.471 ( 7,93 % ) | 108 Mio $ | 31.05.2026 |
| 18.12.2025 | 779.915 ( 0,18 % ) | 43 Mio $ | 31.05.2026 | |
RPI International Holdings 2019 LP
 RPI International Holdings 2019 LP Financial ConglomeratesFinance Functions as an investment fund 0,07 % | 18.06.2020 | 20.500 ( 0,07 % ) | 1 Mio $ | 31.05.2026 |
Aktive Positionen von George Lloyd
| Unternehmen | Position | Beginn |
|---|---|---|
RP Management LLC
 RP Management LLC Financial ConglomeratesFinance Provides biopharma royalty transactions services | Chief Investment Officer | 18.05.2011 |
Royalty Pharma Holdings Ltd.
 Royalty Pharma Holdings Ltd. Financial ConglomeratesFinance Functions as an investment holding company | Direktor/Vorstandsmitglied | 10.06.2020 |
Ehemalige bekannte Positionen von George Lloyd
| Unternehmen | Position | Ende |
|---|---|---|
| ROYALTY PHARMA PLC | Chief Investment Officer | 31.12.2025 |
Davis Polk & Wardwell LLP
 Davis Polk & Wardwell LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Corporate Officer/Principal | - |
Testa, Hurwitz & Thibeault LLP
 Testa, Hurwitz & Thibeault LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Corporate Officer/Principal | - |
Goodwin Procter LLP
 Goodwin Procter LLP Investment ManagersFinance Functions as an alternative investment manager | Corporate Officer/Principal | - |
Ausbildung von George Lloyd
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
12
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
Goodwin Procter LLP
Goodwin Procter LLP Investment ManagersFinance Functions as an alternative investment manager | Finance |
Davis Polk & Wardwell LLP
Davis Polk & Wardwell LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
Testa, Hurwitz & Thibeault LLP
Testa, Hurwitz & Thibeault LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
Princeton University
 Princeton University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
RP Management LLC
RP Management LLC Financial ConglomeratesFinance Provides biopharma royalty transactions services | Finance |
New York Law School
 New York Law School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Royalty Pharma Plc
 Royalty Pharma Plc Pharmaceuticals: MajorHealth Technology Buys and operates a portfolio of biopharmaceutical royalties | Health Technology |
Royalty Pharma Holdings Ltd.
Royalty Pharma Holdings Ltd. Financial ConglomeratesFinance Functions as an investment holding company | Finance |
